Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).
This study will investigate the safety and efficacy of Stereotactic Radiotherapy treatment in combination with aromatase inhibitor and cyclin-dependent kinase (CDK) 4/6 inhibitor for metastatic breast cancer." You may be eligible to join this study if you are aged 18 and above, have histologically proven ER-positive, HER2-negative advanced breast cancer with metastases and receiving an aromatase inhibitor in combination with a CDK 4/6 inhibitor.
Patients with ER-positive, HER2-negative advanced breast cancer receiving an AI in combination with a CDK 4/6 inhibitor with ≤ 5 sites of oligoprogressive disease amenable to SRT.
Patients must have evidence of response to AI and CDK 4/6 inhibitor for a minimum of six months prior to study entry (defined as either stable disease or partial response).
Patients will receive SRT to all sites of Oligoprogressive disease while continuing on AI and CDK 4/6 inhibitors.